At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 1,397 enrolled
Drug / intervention
Rabeprazole sodium +1 moredrug
Likely dose
Rabeprazole sodium 50 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized Double-Blind Parallel Study of Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Mild to Moderate Erosive Gastroesophageal Reflux Disease (GERD)
In Brief
A Phase 3 clinical trial evaluating Rabeprazole sodium and Esomeprazole for Gastroesophageal Reflux Disease (GERD). Completed, enrolled 1,397 participants across 85 sites.
Detailed Summary
The purpose of this study is to investigate the efficacy and safety of Rabeprazole (RAB) Extended-Release (ER) 50 mg versus Esomeprazole (ESO) 40 mg in subjects with erosive gastroesophageal reflux disease (eGERD).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGastroesophageal Reflux Disease (GERD)
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartFeb 2008
First PostedApr 2008
Primary CompletionApr 2009
Study CompletionSep 2009
TodayJul 2026
First PostedApr 15, 2008
Enrollment StartFeb 1, 2008
Primary CompletionApr 1, 2009
Study CompletionSep 1, 2009
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 18.2 years ago
Interventions
Rabeprazole sodiumdrug
Rabeprazole ER 50 mg capsule, once daily for 4-8 weeks.
Esomeprazoledrug
Esomeprazole 40 mg capsule, once daily for 4-8 weeks.